Developing new treatment strategies for hormone receptor positive breast cancer using patient-derived models.
Using patient-derived co-culture models of breast cancer to develop new treatment strategies targeting succinate signaling.
This study is working on better ways to understand hormone receptor positive breast cancer by using tiny lab-grown versions of tumors from patients, which could help create more personalized and effective treatments for people like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10947728 on NIH RePORTER |
What this research studies
This research focuses on creating more accurate models of hormone receptor positive (HR+) breast cancer by using patient-derived tumor organoids and cancer-associated fibroblasts. These models aim to better reflect the diversity of patients and the complexities of the tumor microenvironment, which are often overlooked in current studies. By improving the representation of recurrent and relapsed HR+ breast cancers, the research seeks to enhance understanding of treatment responses and develop new therapeutic strategies. Patients may benefit from more effective and personalized treatment options based on these improved models.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with hormone receptor positive breast cancer, particularly those with recurrent or relapsed disease.
Not a fit: Patients with non-hormone receptor positive breast cancer or those who are not experiencing recurrence may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for patients with hormone receptor positive breast cancer.
How similar studies have performed: Previous research has shown success in developing patient-derived models for other cancers, suggesting potential for similar advancements in HR+ breast cancer.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Muranen, Taru Eliisa — Beth Israel Deaconess Medical Center
- Study coordinator: Muranen, Taru Eliisa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.